Elicio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 19, 2025, reports on the results of Elicio Therapeutics, Inc.'s 2025 Annual Meeting of Stockholders. The meeting was held on May 19, 2025, with a quorum established by 11,172,771 shares representing 70.1% of the voting power.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The primary event is the successful adoption of two governance proposals by the stockholders.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation that both proposals were adopted. The filing notes that the Company is an emerging growth company. No specific risks, contingencies, or unusual items are detailed in this specific report.
Key Facts for Investors to Verify
- Proposal 1 (Director Election): Stockholders elected Karen J. Wilson and Robert R. Ruffolo, Jr., Ph.D., FCPP, to the Board of Directors for three-year terms.
- Voting Results - Karen J. Wilson: 8,588,077 votes For, 420,412 Against, 9,321 Abstain.
- Voting Results - Robert R. Ruffolo, Jr.: 8,980,091 votes For, 28,388 Against, 9,331 Abstain.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Voting Results - Auditor Ratification: 11,133,552 votes For, 29,923 Against, 9,296 Abstain.